CDK
CDK (Cyclin-Dependent Kinase) inhibitors are compounds that block the activity of CDKs, a group of protein kinases that regulate the cell cycle, transcription, and other cellular processes. CDKs are activated by binding to cyclins, and their activity is crucial for the progression of cells through different phases of the cell cycle. Inhibiting CDKs can halt cell division, leading to cell cycle arrest and apoptosis, particularly in cancer cells where CDKs are often dysregulated. CDK inhibitors are widely used in cancer research and have therapeutic potential in treating various cancers. At CymitQuimica, we provide a comprehensive selection of high-quality CDK inhibitors to support your research in cell cycle control, cancer, and therapeutic development.
Found 552 products for "CDK". Showing the first 500.
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
CDK5-IN-1
CAS:CDK5-IN-1: Potent CDK5 inhibitor (<10 nM) used in kidney disease research.Formula:C24H25FN6O3SColor and Shape:SolidMolecular weight:496.56Men 10376
CAS:Men 10376 is a selective antagonist of tachykinin NK-2 receptor. It has a Ki of 4.4 μM for rat small intestine NK-2 receptor.Formula:C57H68N12O10Purity:98%Color and Shape:SolidMolecular weight:1081.22CDK9 inhibitor HH1
CAS:CDK9 inhibitor HH1 (8019-9719) is an inhibitor of the human CDK2-cyclin A2 complex with an IC50 value of 2 μM.Formula:C13H15N3OSPurity:99.92%Color and Shape:SolidMolecular weight:261.34CDK2/PIM1-IN-1
CDK2/PIM1-IN-1 is an inhibitor of the kinases CDK2 (IC50: 0.27 μM) and PIM1 (IC50: 0.67 μM). It can induce apoptosis (cell death) and reduce the expression of TNF-α, which promotes tumors. CDK2/PIM1-IN-1 exhibits antitumor activity.Color and Shape:Odour SolidBSJ-04-132
Selective Cdk4 degrader. Degrades Cdk4 in Molt-4 cells, with no effect on Cdk6 levels. Displays cereblon-dependent degradation.Color and Shape:SolidFDA-Approved Kinase Inhibitor Library
A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.Color and Shape:LiquidRef: TM-L1610
1mgTo inquire10μL*10mM (DMSO)To inquire20μL*10mM (DMSO)To inquire30μL*10mM (DMSO)To inquire50μL*10mM (DMSO)To inquire100μL*10mM (DMSO)To inquire250μL*10mM (DMSO)To inquireLO-3-63
LO-3-63 is a Ribociclib analogue featuring a truncated fumaramide group and acts as a CDK4/6 degrader with PROTAC properties. It degrades CDK4/6 in cells via a CUL4DCAF16-dependent pathway.Color and Shape:Odour SolidYX0597
YX0597 is a potent and selective CDK9 PROTAC degrader that reduces RNA polymerase II S2 phosphorylation and MCL1 expression in GA0518 and AGS cells. It effectively inhibits the growth of GEAC cells (including radioresistant tumors) and suppresses tumor proliferation, metastasis, and cancer stem cells.Color and Shape:Odour Solid[pSer2, pSer5, pSer7]-CTD TFA
Substrate '[pSer2, pSer5, pSer7]-CTD (TFA)' for CDK7 phosphorylates RNA Pol II CTD at ser2, 5, 7.Formula:C98H138F3N21O39Purity:98%Color and Shape:SolidMolecular weight:2291.25MU1210
CAS:MU1210 (compound 12f) acts as an inhibitor of CDC-like kinases Clk1, Clk2, and Clk4 with IC50 values of 8, 20, and 12 nM, respectively, and exhibits IC50 values of 187 and 1309 nM for HIPK1 and DYRK2. Additionally, MU1210 demonstrates favorable pharmacokinetic properties in mice (10 mg/kg, intraperitoneal injection: Cmax=1.24 μM, T1/2=58 minutes; no acute toxicity observed).Formula:C22H16N4OColor and Shape:SolidMolecular weight:352.39EGFR/CDK2-IN-4
EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor targeting EGFR and CDK-2, demonstrating IC50 values of 89.6 nM for EGFR and 165.4 nM for CDK-2.Formula:C24H16N6OS2Purity:98%Color and Shape:SolidMolecular weight:468.55CDK4/6-IN-5
CAS:CDK4/6-IN-5 inhibits CDK4/6; Ki: 0.2 nM (CDK4/D1) & 4.4 nM (CDK6/D3). (WO2019207463A1, A93)Formula:C22H28ClFN6O4SColor and Shape:SolidMolecular weight:527.01Kinase Inhibitor Library
A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;Color and Shape:Odour SolidRef: TM-L1600
1mgTo inquire10μL*10mM (DMSO)To inquire20μL*10mM (DMSO)To inquire30μL*10mM (DMSO)To inquire50μL*10mM (DMSO)To inquire100μL*10mM (DMSO)To inquire250μL*10mM (DMSO)To inquireLL-K8-22
LL-K8-22: potent CDK8/cyclin C degrader; DC50 ~2.5μM; hinders STAT1 phosphorylation; curbs E2F/MYC cancer pathways; for TNBC study.Formula:C37H43N5OColor and Shape:SolidMolecular weight:573.77IV-361
CAS:IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1Formula:C23H32FN5O2SiColor and Shape:SolidMolecular weight:457.625PP-C8
PP-C8: PROTAC CDK12-Cyclin K degrader with DC50s 416/412 nM; synergizes with PARP inhibitor against TNBC.Formula:C43H51FN12O7Color and Shape:SolidMolecular weight:866.94Ribociclib-D6 hydrochloride
Ribociclib-D6 hydrochloride is a deuterated form of Ribociclib hydrochloride (T15730), which is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and has over 1000-fold lower activity against the cyclin B/CDK1 complex.CDK12-IN-6
CAS:CDK12-IN-6, a pyrazolotriazine, strongly inhibits CDK12 (IC50 1.19 μM at 2 mM ATP), but not CDK2/Cyclin E or CDK9/Cyclin T1 (both IC50 >20 μM).Formula:C20H21F2N9Color and Shape:SolidMolecular weight:425.448EGFR/CDK2-IN-2
EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.Formula:C49H32N12O2S2Purity:98%Color and Shape:SolidMolecular weight:884.99SNX7
CAS:SNX7 (WAY-323879) inhibits CDKI pathway; useful for studying aging and related diseases.Formula:C15H14N2OPurity:99.96%Color and Shape:SolidMolecular weight:238.28
